OxyContin’s Reformulation and Substance Use Disorder Treatment: Evidence from Admissions and Facilities

DiNardi, Michael (2025): OxyContin’s Reformulation and Substance Use Disorder Treatment: Evidence from Admissions and Facilities.

Abstract

I examine how the substance use disorder treatment sector responded to the abuse-deterrent reformulation of OxyContin, which contributed to a shift from prescription opioid misuse to heroin and synthetic opioids in the 2010s. States with higher pre-reformulation rates of OxyContin misuse experienced larger increases in heroin treatment admissions across outpatient and inpatient detoxification settings. Substance use disorder treatment facilities also expanded in higher misuse states, driven entirely by an increase in outpatient facilities. Despite increasing availability of medication-assisted treatment services at substance use disorder treatment facilities in higher misuse states, I find no evidence that heroin treatment admissions receiving medication-assisted treatment at these facilities increased. These results indicate that OxyContin’s reformulation increased opioid treatment admissions, shifted the composition of admissions toward heroin, and spurred expansion of outpatient treatment capacity.

• Item Type: MPRA Paper
• Language: English
• Keywords: OxyContin, opioids, substance use, substance use treatment
• Subjects: I - Health, Education, and Welfare > I1 - Health > I11 - Analysis of Health Care Markets; I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy ; Regulation ; Public Health

References

Alpert, A., Evans, W. N., Lieber, E. M. J., and Powell, D. 2022. Origins of the Opioid Crisis and its Enduring Impacts. The Quarterly Journal of Economics, 137(2): 1139-1179.

Alpert, A., Powell, D., and Pacula, R. L. 2018. Supply-side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-deterrent Opioids. American Economic Journal: Economic Policy, 10(4): 1-35.

Bailey, J., Lu, T., and Vogt, P. 2022. Certificate-of-need Laws and Substance Use Treatment. Substance Abuse Treatment, Prevention, and Policy, 17: 38.

Barnes, H., Chen, A. J., McHugh, M. D., and Richards, M. R. 2025. Public Insurance Expansions and Labor Demand in Physician Practices. Journal of Human Resources, 60(6): 1881-1914.

Beheshti, D. 2019. Adverse Health Effects of Abuse-deterrent Opioids: Evidence from the Reformulation of OxyContin. Health Economics, 28(12): 1449-1461.

Bondurant, S. R., Lindo, J. M., and Swensen, I. D. 2018. Substance Abuse Treatment Centers and Local Crime. Journal of Urban Economics, 104: 124-133.

Campbell, B. K., Tillotson, C. J., Choi, D., Bryant, K., DiCenzo, J., Provost, S. E., Zammarelli, L., Booth, R. E., and McCarty, D. 2010. Predicting Outpatient Treatment Entry Following Detoxification for Injection Drug Use: The Impact of Patient and Program Factors. Journal of Substance Abuse Treatment. 38: S87-S96.

Cheetham, A., Picco, L., Barnett, A., Lubman, D. I., and Nielsen, S. 2022. The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy. Substance Abuse and Rehabilitation, 13: 1-12.

Cho, D., Garcia, D., Montes, J. and Weingarden, A. 2021. Labor Market Effects of the Oxycodone-Heroin Epidemic. Finance and Economics Discussion Series 2021-025. Washington: Board of Governors of the Federal Reserve System, https://doi.org/10.17016/FEDS.2021.025.

Ciccarone, D. 2017. Fentanyl in the US Heroin Supply: A Rapidly Changing Risk Environment. International Journal of Drug Policy, 45: 107-111.

Ciccarone, D. 2019. The Triple Wave Epidemic: Supply and Demand Drivers of the US Opioid Overdose Crisis. International Journal of Drug Policy, 71: 183-188.

Cicero, T. J., Ellis, M. S., and Harvey, J. 2015. Shifting Patterns of Prescription Opioid and Heroin Abuse in the United States. New England Journal of Medicine, 373: 1789-1790.

Cicero, T. J., Ellis, and Surratt. H. L. 2012. Effect of Abuse-deterrent formulation of OxyContin. New England Journal of Medicine, 367: 187-189.

Connery, H. S. 2015. Medicaid-assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions. Harvard Review of Psychiatry, 23(2): 63-75.

Coplan, P. M., Kale, H., Sandstrom, L., Landau, C., and Chilcoat, H. D. 2013. Changes in Oxycodone and Heroin Exposures in the National Poison Data System after Introduction of Extended-release Oxycodone with Abuse-deterrent Characteristics. Pharmacoepidemiology and Drug Safey, 22: 1274-1282.

Corredor-Waldron, A. and Currie, J. 2022. Tackling the Substance Use Disorder Crisis: The Role of Access to Treatment Facilities. Journal of Health Economics, 81: 102579.

Courtemanche, C., Friedson, A., Koller, A. P., and Rees, D. I. 2019. The Affordable Care Act and Ambulance Response Times. Journal of Health Economics, 67: 102213.

Creedon, T. B., Ali, M. M., and Schuman-Olivier, Z. 2023. Trends in Buprenorphine Prescribing for Opioid Use Disorder by Psychiatrists in the US from 2003 to 2021. JAMA Health Forum, 4(4): e230221.

DiNardi, M. 2021. Affordable Care Act Medicaid Expansions and the Nurse Labor Market. Southern Economic Journal, 88(1): 367-398.

DiNardi, M. 2021. The Release of Abuse-deterrent OxyContin and Adolescent Heroin Use. 2021. Drug and Alcohol Dependence, 229(Part B): 109114.

DiNardi, M., Swann, W. L., and Kim, S. Y. 2022. Racial/ethnic Residential Segregation and the Availability of Opioid and Substance Use Treatment Facilities in US Counties, 2009-2019. SSM – Population Health, 20: 101289.

Dillender, M. 2022. How Do Medicaid Expansions Affect the Demand for Healthcare Workers? Evidence from Vacancy Postings. Journal of Human Resources, 57(4): 1350-1393.

Evans, M. F., Harris, M. C., & Kessler, L. M. 2022. The Hazards of Unwinding the Prescription Opioid Epidemic: Implications for Child Maltreatment. American Economic Journal: Economic Policy, 14(4), 192–231.

Evans, W. N., Lieber, E. M. J., and Power, P. 2019. How the Reformulation of OxyContin Ignited the Heroin Epidemic. Review of Economics and Statistics, 101(1): 1-15.

Farhoudian, A., Razaghi, E., Hooshyari, Z., Noroozi, A., Pilevari, A., Mokri, A., Mohammadi, M. R., and Malekinejad, M. 2022. Barriers and Facilitators to Substance Use Disorder Treatment: An Overview of Systematic Reviews. Substance Abuse: Research and Treatment, 16: 1-11.

French, M. T., Popovici, I., and Tapsell, L. 2008. The Economic Costs of Substance Abuse Treatment: Updated Estimates and Cost Bands for Program Assessment and Reimbursement. Journal of Substance Abuse Treatment, 35: 462-469.

Garthwaite, C. 2012. The Doctor Might See You Now: The Supply Side Effects of Public Health Insurance Expansions. American Economic Journal: Economic Policy, 4(3): 190-215.

Goedel, W. C., Shapiro, A., Cerda, M., Tsai, J. W., Hadland, S. E., and Marshall, B. D. 2020. Association of Racial/Ethnic Segregation with Treatment Capacity for Opioid Use Disorder in Counties in the United States. JAMA Network Open, 3(4): e203711.

Goodman-Bacon. 2021. Difference-in-differences with Variation in Treatment Timing. Journal of Econometrics, 225(2): 254-277.

Grooms, J. and Ortega, A. 2019. Examining Medicaid Expansion and the Treatment of Substance Use Disorders. American Economic Association Papers and Proceedings, 109: 187-191.

Heflin, C. and Sun, X. 2022. Food Insecurity and the Opioid Crisis. The ANNALS of the American Academy of Political and Social Science, 703(1): 262-284.

Jackson, J. R., Harle, C. A., Silverman, R. D., Simon, K., and Menachemi, N. 2020. Characterizing Variability in State-level Regulations Governing Opioid Treatment Programs. Journal of Substance Abuse Treatment, 115: 108008.

Jehan, S., Zahnd, W. E., Wooten, N. R., and Seay, K. D. 2024. Geographic Variation in Availability of Opioid Treatment Programs across U.S. Communities. Journal of Addictive Diseases, 42(2): 136-146.

Knudsen, H. K., Abraham, A. J., and Oser, C. B. 2011. Barriers to the Implementation of Medication-assisted Treatment for substance Use Disorders: The Importance of Funding Policies and Medical Infrastructure. Evaluation and Program Planning, 34(4): 375-381.

Krawczyk, N., Rivera, B. D., Jent, V., Keyes, K.M, Jones, C. M., and Cerda, M. 2022. Has the Treatment Gap for Opioid Use Disorder Narrowed in the U.S.?: A Yearly Assessment from 2010 to 2019. International Journal of Drug Policy, 110: 103786.

Kolodny, A., Courtwright, D. T., Hwang, C. S., Kreiner, P., Eadie, J. L. Clark, T. W., and Alexander, G. C. 2015. The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction. Annual Review of Public Health, 36: 559-574.

Mackenzie-Liu, M. 2021. From Fostering Hope to Lingering Harm: The Unintended Impact of OxyContin Reformulation on Child Welfare Utilization. Social Service Review, 95: 35-65.

Maclean, J. C., Mallat, J., Ruhm, C. J., and Simon, K. 2021. Economic Studies on the Opioid Crisis: A Review. National Bureau of Economic Research, Working Paper No. 28067. http://www.nber.org/papers/w28067.

Mallat, J. 2022. Policy-induced Substitution to Illicit Drugs and Implications for Law Enforcement Activity. American Journal of Health Economics, 8: 30-64.

Noh, S. and Brown, C. H. 2018. Factors Associated with the Number of Substance Abuse Nonprofits in the U.S. States: Focusing on Medicaid Expansion, Certificate of Need, and Ownership. Nonprofit Policy Forum, 9(2): 20170010.

Olfson, M., Zhang, V., Schoenbaum, M., and King, M. 2020. Buprenorphine Treatment by Primary Care Providers, Psychiatrists, Addiction Specialists, and Others. Health Affairs, 39(6): 984-992.

Park, S. and Powell, D. 2021. Is the Rise in Illicit Opioids Affecting Labor Supply and Disability Claiming Rates?. Journal of Health Economics, 76: 102430.

Powell, D. 2023. Growth in Suicide Rates Among Children During the Illicit Opioid Crisis. Demography, 60(6): 1843-1875.

Powell, D. and Pacula, R. L. 2021. The Evolving Consequences of OxyContin Reformulation on Drug Overdoses. American Journal of Health Economics, 7(1): 41-67.

Roman, P. M., Abraham, A. J., and Knudsen, H. K. 2011. Using Medication-assisted Treatment for Substance Use Disorders: Evidence of Barriers and Facilitators of Implementation. Addictive Behaviors, 36(6): 584-589.

Ryan, O., D. Murphy, and L. Krom. “Vital Signs: Taking the Pulse of the Addiction Treatment Workforce, A National Report.” Version 1. Kansas City, MO: Addiction Technology Transfer Center, National Office in residence at the University of Missouri-Kansas City, 2012

Takahashi, L. M. and Dear, M. J. 1997. The Changing Dynamics of Community Opposition to Human Service Facilities. Journal of the American Planning Association, 63(1): 79-93.

Saloner, B. and Maclean, J. M. 2020. Specialty Substance Use Disorder Treatment Admissions Steadily Increased in the Four Years After Medicaid Expansion. Health Affairs, 39(3): 453-461.

Shakya, S. and Bretschneider-Fires, C. 2025. The Effect of Substance Use Certificate-of-Need Laws on Access to Substance Use Disorder Treatment Facilities. Southern Economic Journal, 92(1): 87-110.

Substance Abuse and Mental Health Services Administration. 2020a. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. HHS Publication No. PEP20-07-01-001, NSDUH Series H-55. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/.

Substance Abuse and Mental Health Services Administration. 2020b. National Survey of Substance Abuse Treatment Services (N-SSATS): 2019. Data on Substance Abuse Treatment Facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration.

Swensen, I. 2015. Substance-abuse Treatment and Mortality. Journal of Public Economics, 122: 13-30.

U.S. Congress, Joint Economic Committee. 2017. The Cost of the Opioid Crisis: The Impact on the Labor Market and the Economy. Washington, DC: U.S. Joint Economic Committee. https://www.jec.senate.gov/public/_cache/files/67bced7f-4232-40ea-9263-f033d280c567/jec-cost-of-opioids-issue-brief.pdf.

U.S. Department of Health and Human Services. 2015. Examining Substance Use Disorder Treatment Demand and Provider Capacity in a Changing Health Care System: Initial Findings Report. Available at https://aspe.hhs.gov/sites/default/files/migrated_legacy_files//146281/ExamSUD.pdf. Accessed April 14, 2025.

U.S. General Accounting Office. 2003. Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem. GAO-04-110. Washington, DC: U.S. General Accounting Office, 2003. https://www.gao.gov/assets/gao-04-110.pdf.

Van Zee, A. 2009. The Promotion and Marking of OxyContin: Commercial Triumph, Public Health Tragedy. American Journal of Public Health, 99(2): 221-277.

Wakeman S.E., Larochelle M.R., Ameli O., Chaisson, C. E., McPheeters, J. T., Crown, Wi. H., Azocar, F., and Sanghavi, D. M. 2020. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Network Open, 3(2): e1920622. doi:10.1001/jamanetworkopen.2019.20622

Wu, L., Woody, g., Yang, C., Mannelli, P., and Blazer, D. 2011. Differences in onset and abuse/dependence episodes between prescription opioids and heroin: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Substance Abuse and Rehabilitation, 2: 77-88.

Zoorob, M. 2019. Fentanyl Shock: The Changing Geography of Overdose in the United States. International Journal of Drug Policy, 70: 40-46.